Global GLP-1 & Obesity Volume
Eli Lilly Share (Mounjaro/Zepbound)
Direct US / Global Competitor
Projected Valuation Delta
+$48.2B
Estimated Market Cap Impact
Brand Recall Score
91/100
Consumer GLP-1 Brand Salience
Global Obesity & Diabetes GLP-1 Market Share Dynamics
Real-time projection based on capacity scaling, rebrand sentiment, and pricing aggression
Novo
Eli Lilly
Other Competitors (Amgen, Pfizer, Roche)
⚡ Supply Chain & Manufacturing Status
Optimized & Scaled
With $14.5B committed to fill-finish and API facilities, Novo eliminates Wegovy supply rationing, neutralizing Lilly's previous 2024-2026 availability advantage.
Estimated Annual Dose Throughput: 245M units/year
🏛️ Corporate Rebrand & Strategic Context
- Rebrand Rationale: Dropping "Nordisk" simplifies consumer direct-to-patient communications in obesity care while retaining diabetes heritage.
- Lilly Competitive Pressure: Lilly's tirzepatide captured upwards of 54.8% of US GLP-1 new patient starts in mid-2026.
- Pipeline Horizon: Next-generation dual and triple agonists (CagriSema, Amycretin) require accelerated R&D share to protect terminal value.